Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.

Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA, Cockram CS.

Kidney Int. 2000 Feb;57(2):590-600.

2.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

3.
4.
5.

Treatment of microalbuminuria in patients with type 2 diabetes mellitus.

Jerums G, MacIsaac RJ.

Treat Endocrinol. 2002;1(3):163-73. Review.

PMID:
15799209
6.

Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.

Sasongko TH, Nagalla S, Ballas SK.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD009191. doi: 10.1002/14651858.CD009191.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;(6):CD009191.

PMID:
23543572
7.

Time to abandon microalbuminuria?

Ruggenenti P, Remuzzi G.

Kidney Int. 2006 Oct;70(7):1214-22. Epub 2006 Jul 26. Review.

8.

The management of diabetic proteinuria. Which antihypertensive agent?

Cooper ME, Doyle AE.

Drugs Aging. 1992 Jul-Aug;2(4):301-9. Review.

PMID:
1504444
9.

Treatment of patients with essential hypertension and microalbuminuria.

Redon J.

Drugs. 1997 Dec;54(6):857-66. Review.

PMID:
9421693
10.

Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life.

Cooper ME, Vranes D, Rumble JR.

Drugs Aging. 1996 Jan;8(1):38-46. Review.

PMID:
8785467
11.

Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta-regression analysis.

Viazzi F, Muiesan ML, Schillaci G, Salvetti M, Pucci G, Bonino B, Signori A, Pontremoli R.

J Hypertens. 2016 Sep;34(9):1689-97. doi: 10.1097/HJH.0000000000000991. Review.

PMID:
27254313
12.

[JMIC-B study and its sub-analyses: effect of nifedipine in Japanese hypertensive patients with coronary artery disease].

Yui Y.

Drugs. 2006;66 Spec No 1:25-7. Review. Japanese. Erratum in: Drugs. 2007;67(13):1849.

PMID:
18200776
13.

Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril.

Schlueter W, Keilani T, Batlle DC.

Am J Cardiol. 1993 Dec 30;72(20):37H-44H. Review.

PMID:
8285181
14.

Factors Associated with Microalbuminuria Remission in Patients with Type 2 Diabetes: Importance of Early Intervention for Microalbuminuric Patients (TSUGARU STUDY).

Nakamura N, Narita I, Fujita T, Murakami R, Shimada M, Nakamura M, Osawa H, Yamabe H, Okumura K; DIABETIC NEPHROPATHY TREATMENT STUDY GROUP.

In Vivo. 2017 May-Jun;31(3):285-290. Review.

15.

Vascular response to vasodilator treatment in microalbuminuric diabetic kidney disease.

Futrakul N, Futrakul P.

World J Nephrol. 2013 Nov 6;2(4):125-8. doi: 10.5527/wjn.v2.i4.125. Review.

16.

Supplemental Content

Support Center